bioMerieux (OTCMKTS:BMXMF) Raised to “Hold” at Zacks Research

bioMerieux (OTCMKTS:BMXMF) was upgraded by analysts at Zacks Research to a “hold” rating in a report issued on Tuesday,Zacks.com reports.

Several other research analysts also recently issued reports on the stock. Deutsche Bank Aktiengesellschaft downgraded shares of bioMerieux from a “buy” rating to a “hold” rating in a research report on Friday, April 24th. BNP Paribas Exane lowered shares of bioMerieux to a “neutral” rating in a report on Wednesday, January 28th. Four research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the company presently has an average rating of “Hold”.

bioMerieux Stock Performance

BMXMF remained flat at $77.38 during trading on Tuesday. The company’s stock had a trading volume of 577 shares, compared to its average volume of 204. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.48 and a current ratio of 2.39. The company’s 50 day moving average price is $107.96 and its 200 day moving average price is $118.41. bioMerieux has a 52-week low of $77.38 and a 52-week high of $152.00.

bioMerieux Company Profile

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.